This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.4 (achondroplasia) | Special Copayment Reduction: V228 (rare disease) |
| B. Synonyms | Achondroplasia, Hypochondroplasia, congenital osteosclerosis |
| C. Adult onset | Likelihood of first presentation in adulthood: low — most cases are diagnosed at birth or by prenatal ultrasound, but complications such as spinal stenosis and hydrocephalus may progress in adulthood, causing symptoms to appear or worsen. |
| 1. History | Records in ancient Egyptian wall paintings → 1878 first named by Parrot → 1994 FGFR3 gene identified → 1994 G380R variant identified → 2021 FDA approval of vosoritide. |
| 2. Causes | FGFR3 gene p.G380R point mutation (>97%). Autosomal dominant, about 80% new mutations. FGF receptor gain-of-function variant inhibiting chondrocyte proliferation. |
| 3. Genetics | FGFR3: 4p16.3, autosomal dominant. Homozygous form lethal. G380R CpG mutation hotspot. Hypochondroplasia due to weaker FGFR3 variants such as N540K. |
| 4. General epidemiology | 1 in 15,000~25,000 births. The most common nonlethal skeletal dysplasia. About 250,000 people worldwide. Advanced paternal age increases the risk of new mutations. |
| 5. Pathophysiology | FGFR3 hyperactivation → activation of STAT1/MAPK pathways → inhibition of growth plate chondrocyte proliferation and differentiation → impaired long bone growth. Antagonism by the CNP/NPR-B pathway. |
| 6. Symptoms | Rhizomelic short stature (mean height male 131cm / female 124cm), macrocephaly, midface hypoplasia, trident hand, lumbar lordosis, recurrent otitis media, sleep apnea. |
| 7. Signs | Foramen magnum stenosis (risk of sudden infant death), spinal stenosis (lower limb paralysis, claudication), hydrocephalus, hip flexion contracture, genu varum. Impaired cerebrospinal fluid flow. |
| 8. Screening | Prenatal ultrasound (limb shortening after 24 weeks of gestation), fetal cfDNA (noninvasive prenatal testing), FGFR3 analysis by chorionic villus sampling or amniocentesis. |
| 9. Diagnosis | Clinical and radiologic findings (rhizomelic shortening, characteristic pelvic and cranial shape) + molecular genetic confirmation of FGFR3. Standard skeletal radiograph panel. |
| 10. Treatment | Vosoritide (CNP analog, 2021 FDA / 2022 EMA approval, children under 5 years with open growth plates). Limb lengthening. Foramen magnum decompression. Spinal stenosis surgery. Multidisciplinary management. |
| 11. Prognosis | Near-normal life expectancy (with management of foramen magnum stenosis in infancy). Main complications: spinal stenosis, sleep apnea, hearing loss. Normal intelligence. |
| 12. Prevention | Genetic counseling, prenatal diagnosis, preimplantation genetic testing (PGT). Regular follow-up to prevent complications (neurosurgery, otolaryngology, polysomnography). |
| 13. References | Shirley ED et al. JAAOS 2009; Ornitz DM et al. Hum Mol Genet 2017; Hoover-Fong J et al. Nat Rev Dis Primers 2021 … and 7 others |
The history of achondroplasia is as old as human civilization. Figures with the characteristic body shape of achondroplasia are depicted in wall paintings and statues from the Fourth Dynasty of ancient Egypt (around 2600 BC), and the Egyptian god Bes is also interpreted as having the achondroplasia phenotype. Figures with similar phenotypes are also found in ancient Roman and Greek artifacts. In medieval Europe, people with achondroplasia sometimes held a special social position as court jesters.
Modern medical description began in 1878 when the French physician Joseph-Marie Jules Parrot gave this disease the name 'achondroplasia.' Based on autopsy findings, Parrot inferred that a defect of endochondral ossification was the underlying lesion, but the molecular mechanism could not be known at the time. Thereafter, throughout the 20th century, the radiologic features were systematized, and the structural and cytologic abnormalities of the growth plate were elucidated.
The milestone in molecular pathogenesis came in 1994. Two research groups independently discovered mutations in the FGFR3 (fibroblast growth factor receptor 3) gene in patients with achondroplasia. In the same year, Shiang et al. and Rousseau et al. reported that in almost all patients with achondroplasia the p.G380R (Gly380Arg) variant occurs, resulting from a G→A (or G→C) substitution at nucleotide 1138 of the FGFR3 gene. This variant is located at a CpG dinucleotide hotspot where two different substitutions can occur at the same codon, so the rate of new mutations is high.
In 1999, Deng et al. demonstrated in a mouse model that FGFR3 gain-of-function variants reproduce the achondroplasia phenotype, establishing the genotype-phenotype association. Subsequently, the FGFR3 downstream signaling pathways—STAT1, MAPK (ERK), PI3K—and the mechanisms of inhibition of chondrocyte proliferation and differentiation were elucidated in detail. In 2004, Yasoda et al. discovered that C-type natriuretic peptide (CNP) antagonizes FGFR3 signaling and promotes cartilage growth, proposing it as a therapeutic target.
Vosoritide, developed on the basis of this discovery, is a CNP analog that was approved as a treatment for achondroplasia in children aged 5 years and older with open growth plates by the US FDA in November 2021 and by the European EMA in 2022. This was the first approval of a drug therapy in the history of achondroplasia, achieved just 27 years after elucidation of the molecular mechanism. Currently, various FGFR3 inhibitors, tyrosine kinase inhibitors, and soluble receptor agents are in clinical trials, and the therapeutic horizon continues to expand.
Achondroplasia is caused by pathogenic variants in the FGFR3 (Fibroblast Growth Factor Receptor 3) gene, located on the short arm of chromosome 4 (4p16.3). FGFR3 is a transmembrane receptor for fibroblast growth factors (FGF) and a key factor regulating the proliferation and differentiation of chondrocytes in the growth plate. Under normal conditions, FGFR3 acts in the direction of inhibiting growth, serving to keep cartilage growth balanced.
Among variants causing achondroplasia, p.G380R (Gly380Arg) accounts for more than 97% of all cases. In this variant, glycine 380 in the transmembrane domain of the FGFR3 protein is replaced by arginine, arising from a G→A transition at nucleotide 1138 (Gly→Arg, about 98%) or, rarely, a G→C transversion (about 2%). This position is a CpG dinucleotide hotspot, where new mutations occur at high frequency through spontaneous demethylation-deamination reactions. In the remaining less than 3%, other variants at the same codon or adjacent sites (e.g., p.G375C, p.G346E) cause a similar clinical phenotype.
The mode of inheritance is autosomal dominant. Children of an affected parent inherit the disease with a 50% probability. However, in actual clinical practice, about 80% of patients have new (de novo) mutations and are born to normal parents, and the mutations are known to arise mainly during paternal spermatogenesis. As paternal age increases, the rate of new mutations rises, because the frequency of replication errors in spermatogonia increases with aging.
Homozygous achondroplasia occurs in children born to two affected parents and is a lethal disease that causes far more severe skeletal developmental failure than the heterozygous form, almost invariably resulting in death in infancy (respiratory failure). Heterozygous achondroplasia is nonlethal, but the homozygous form shows a completely different, lethal phenotype.
Hypochondroplasia is caused by variants in the same FGFR3 gene as achondroplasia but is an allelic disorder showing a milder phenotype due to weaker gain-of-function variants (mainly p.N540K, p.N540S, p.K650Q, etc.). There is limb shortening, but it is less severe than in achondroplasia, and macrocephaly and midface hypoplasia are mild or absent. Clinically, it is included in the differential diagnosis of achondroplasia. Congenital osteosclerosis is also included in the Q77.4 code group and is used as a concept encompassing various skeletal abnormalities based on defects of endochondral ossification.
The FGFR3 gene is located on the short arm of chromosome 4 (4p16.3) and consists of 19 exons. The FGFR3 protein is a receptor tyrosine kinase consisting of an extracellular FGF-binding domain (three IgG-like domains), a single transmembrane domain, and an intracellular tyrosine kinase domain. Glycine 380, located in the transmembrane domain, is a key residue of the alpha-helical structure; when it is replaced by arginine, receptor dimerization is promoted in a ligand-independent manner and the tyrosine kinase is constitutively activated.
The mode of inheritance is autosomal dominant, but phenotypic severity varies by genotype. The heterozygous p.G380R variant causes typical achondroplasia, and the homozygous state shows a lethal phenotype. Variants at other sites of the same FGFR3 gene form a spectrum including thanatophoric dysplasia (TD) types I and II (K650E: TDII; R248C/S249C, etc.: TDI), hypochondroplasia (N540K, etc.), and SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans; K650M). In general, the more a variant activates the kinase domain, the more lethal the phenotype.
Because of the characteristics of its CpG location, the p.G380R variant has a higher frequency of de novo mutation than other rare gene variants, and it arises markedly more often in paternal than in maternal germ cells. This is related to the fact that paternal germ cells continue to divide even after reproductive capacity is acquired, increasing the opportunity for mutation accumulation. According to studies, more than about 95% of new variants are of paternal origin, and the risk increases gradually at paternal ages of 35 years or older.
Molecular genetic testing methods include direct sequencing of FGFR3 exon 10 (detection of p.G380R), allele-specific PCR, or skeletal dysplasia panel testing using next-generation sequencing (NGS). When the p.G380R variant is confirmed in a clinically typical phenotype, the diagnosis is established. When there are atypical findings or p.G380R is negative, analysis of the entire FGFR3 gene and other skeletal dysplasia gene panels are needed. Genetic confirmation is essential for family counseling, prenatal diagnosis, and assessment of treatment eligibility (confirming eligibility for vosoritide treatment).
Hypochondroplasia is caused by variants such as FGFR3 p.N540K (about 70%), p.N540S, and p.K650Q, and shows a milder phenotype because the degree of increased kinase activity is lower than in achondroplasia. Differentiation between the two diseases is clinically important; in hypochondroplasia, macrocephaly, midface hypoplasia, and trident hand are uncommon, and radiologic findings are less characteristic. Molecular genetic testing is key to clinical differentiation, and both diseases share autosomal dominant inheritance with new mutations accounting for the majority.
Achondroplasia is the most common nonlethal skeletal dysplasia, occurring at a frequency of 1 in 15,000~25,000 births in all ethnicities and regions worldwide. The number of patients worldwide is estimated at about 250,000, and about 5,000~10,000 new patients are born each year. It occurs with equal frequency in males and females with no sex ratio difference, and no significant differences by race or ethnicity have been reported.
As mentioned above, about 80% are new (de novo) mutations born to normal parents, and the remaining 20% are inherited in an autosomal dominant manner from an affected (heterozygous) parent. When two affected parents have children, 25% of the children have the lethal homozygous form, 50% are affected heterozygotes, and 25% are normal. Between one affected parent and one normal parent, 50% of children are affected.
The paternal age effect is pronounced, with the frequency of new mutations increasing significantly at paternal ages of 35 years or older. Some studies have reported that the rate of new achondroplasia mutations in older fathers (45 years or older) is 5~7 times higher than in young fathers (25~29 years). Together with the increase in older fathers due to social trends, this predicts a gradual rise in the incidence of achondroplasia.
In Korea, the Q77.4 disease group including achondroplasia is eligible for rare disease Special Copayment Reduction (V228), and the number of patients and medical utilization are tracked through Health Insurance Review & Assessment Service (HIRA) registration data. The number of registered patients in Korea is estimated to be in the hundreds, and the number of registered and managed patients is expected to increase with insurance coverage of new treatments such as vosoritide. With the universalization of prenatal ultrasound, the prenatal diagnosis rate is rising, and noninvasive prenatal testing (NIPT)-based technologies for detecting fetal skeletal dysplasias are advancing.
The incidence of hypochondroplasia is known to be similar to or slightly lower than that of achondroplasia, but because of its milder phenotype, diagnosis is sometimes delayed or missed, so the actual frequency may be undercounted. Awareness of this disease is improving among both physicians and patients worldwide, and the universalization of molecular genetic diagnosis is contributing to improved diagnosis rates.
The core pathophysiology of achondroplasia is growth plate dysfunction due to constitutive activation of FGFR3. Normal long bone growth occurs through the sequential process of chondrocytes in the growth plate undergoing proliferation (proliferative zone), hypertrophy (hypertrophic zone), cartilage matrix secretion, calcification, and replacement by bone. FGFR3 normally serves to appropriately inhibit this process, but when the p.G380R variant causes the receptor to dimerize even without ligand and become constitutively activated, inhibitory signaling to chondrocytes is excessively enhanced.
Activated FGFR3 inhibits chondrocyte growth mainly through two downstream signaling pathways. First, the STAT1 (Signal Transducer and Activator of Transcription 1) pathway: when activated FGFR3 phosphorylates STAT1 through JAK kinase, expression of a cell cycle inhibitor (p21WAF1/CIP1) increases and chondrocyte proliferation is blocked. Second, the MAPK/ERK pathway: FGFR3 activation inhibits chondrocyte differentiation and hypertrophy through the Ras-Raf-MEK-ERK cascade and regulates the activity of cartilage/bone differentiation transcription factors such as Sox9 and Runx2. Simultaneous hyperactivation of these two pathways reduces the number of proliferating chondrocytes and the size of hypertrophic chondrocytes in the growth plate, markedly slowing the growth rate of the long bones of the limbs.
In normal skeletal growth, CNP (C-type Natriuretic Peptide) generates cGMP through the NPR-B (natriuretic peptide receptor-B) receptor and antagonizes the MAPK/ERK pathway, promoting chondrocyte growth. In the state of FGFR3 hyperactivation, the CNP/NPR-B pathway is relatively weakened, so growth-inhibitory signaling becomes even more dominant. Vosoritide, a CNP analog, was developed on the principle of stimulating NPR-B to antagonize MAPK signaling downstream of FGFR3, thereby restoring growth plate growth.
The skull vault and facial bones grow by intramembranous ossification, so they are less affected by the impairment of endochondral ossification and grow close to normal. However, the skull base depends on endochondral ossification, so its growth is limited, resulting in foramen magnum stenosis and impaired cerebrospinal fluid flow. Limited cartilage growth of the vertebral bodies narrows the spinal canal, and spinal stenosis progresses in adulthood. Poor growth of the midface results in midface hypoplasia, and otitis media with effusion and conductive hearing loss due to Eustachian tube dysfunction occur frequently.
Symptoms of achondroplasia are evident from birth or infancy, and various complications are added with growth. The core clinical feature is short stature with rhizomelic limb shortening, in which shortening of the humerus and femur (proximal segments) is more prominent than that of the forearm and lower leg.
Height: Mean adult height is about 131cm in men and about 124cm in women, with a range of standard deviation. Trunk length is relatively less affected, giving the appearance of limbs short relative to the trunk.
Craniofacial features: Macrocephaly is characteristic, accompanied by frontal bossing and midface hypoplasia. Occipital prominence, a depressed nasal bridge, and an upturned nose are observed. This craniofacial morphology causes Eustachian tube dysfunction, so otitis media with effusion recurs in childhood, and if not properly treated, it leads to conductive hearing loss.
Limbs and hands: In the upper limbs, the trident hand is characteristic. The fingers are short and there is a gap between the ring and middle fingers, forming a trident shape, and finger extension is limited. Full extension of the elbow is often impossible. In the lower limbs, genu varum is common.
Spine and posture: Lumbar lordosis is prominent, and thoracolumbar kyphosis (gibbus deformity) typically appears in infancy and disappears with the start of walking, but persists in some. The chest is narrow and the ribs short, so respiratory restriction may appear in infancy. Progressive spinal stenosis develops in children and adults, causing low back pain, radiating leg pain, claudication, and voiding dysfunction.
Neurological complications: The most dangerous complication in infancy is compression of the medulla and cervical spinal cord due to foramen magnum stenosis. Irregular breathing during sleep, cyanosis, apnea, hypotonia or limb paralysis, and sudden infant death (SIDS) may occur. Hydrocephalus may also appear in infancy, with intracranial venous hypertension and impaired cerebrospinal fluid absorption known as the mechanisms. Obstructive sleep apnea commonly occurs from childhood through adulthood due to midface hypoplasia and upper airway narrowing.
Other symptoms: Accompanying features include growth delay (achondroplasia-specific charts must be used as the standard growth curves for weight), a tendency toward obesity, limping (neurogenic claudication due to lumbar stenosis), and delayed language development due to recurrent otitis media (related to hearing loss).
The physical and radiologic signs of achondroplasia change with age, and understanding the features at each age is important for clinical evaluation.
Signs in the neonatal period and infancy: At birth, rhizomelic limb shortening, macrocephaly, trident hand, and frontal bossing are evident. Hypotonia may be present. The most important sign is foramen magnum stenosis, which may present with posterior neck pain, limb paralysis, and apnea during sleep. Head MRI confirms narrowing of the foramen magnum and compression of the cervical spinal cord. Meningocele or signs of hydrocephalus (rapid increase in head circumference, bulging anterior fontanelle, sunset sign) may also appear.
Radiologic signs: Typical skeletal radiographic findings are key to the diagnosis of skeletal dysplasia. Skull: enlarged cranial vault, narrowed skull base, narrowed foramen magnum. Chest: short horizontal ribs, champagne glass-shaped chest. Spine: caudal narrowing of the lumbar interpediculate distance (narrowing from L1→L5 — the opposite of normal). Pelvis: horizontal iliac wings (champagne glass pelvis), narrow sacrosciatic notch. Long bones: short, thick tubular bones, bullet-shaped proximal femur, physeal sclerotic lines. Hands: short tubular bones, trident arrangement.
Signs in childhood and adolescence: Genu varum, lumbar hyperlordosis, thoracolumbar kyphosis (gibbus) — surgery is considered if it persists before walking. Conductive hearing loss and abnormal tympanic membrane findings due to recurrent otitis media. Snoring and apnea during sleep due to increased nasal resistance and adenoid hypertrophy. Neurogenic claudication may appear from adolescence.
Signs in adulthood: Spinal stenosis is the most important adult complication, with compression of the spinal cord and nerve roots occurring in the lumbar region (most commonly L3-L4). The main symptoms are leg pain and weakness on walking, bladder and bowel dysfunction, and low back pain. Hip flexion contracture worsens lumbar hyperlordosis. Obstructive sleep apnea persists in adults as well and acts as a risk factor for cardiovascular complications.
Laboratory findings: There are no specific blood test findings. Molecular genetic confirmation of an FGFR3 variant is the criterion for confirmation. In imaging, evaluation of the degree of stenosis by spinal MRI, measurement of ventricular size and foramen magnum diameter by brain MRI, and evaluation of the severity of sleep apnea by polysomnography are important.
Universal screening of the general population for achondroplasia is not currently performed, but systematic screening is carried out in high-risk groups (presence of an affected parent, abnormal prenatal ultrasound findings).
Prenatal ultrasound: This is the primary screening method for achondroplasia. Achondroplasia is suspected when findings such as shortening of the long bones of the limbs (femur length < 5th percentile), macrocephaly, frontal bossing, trident hand, and a narrow chest are observed on standard prenatal ultrasound after 24 weeks of gestation. However, it may be difficult to differentiate achondroplasia from other skeletal dysplasias (thanatophoric dysplasia, hypochondroplasia, etc.) by ultrasound alone. When there is an affected parent, close ultrasound monitoring is needed from 20 weeks of gestation.
Noninvasive prenatal testing (NIPT/cfDNA): Recently, technology for detecting the FGFR3 p.G380R variant through analysis of cell-free fetal DNA (cffDNA) in maternal plasma has been introduced into clinical practice. This method can assess the possibility of achondroplasia from 10~12 weeks of gestation without invasive testing, making it a useful tool for early screening. However, a positive result must be confirmed by chorionic villus sampling or amniocentesis.
Invasive prenatal diagnosis: When an abnormality is suspected on ultrasound or NIPT, or when there is an affected parent, fetal DNA is obtained by chorionic villus sampling (CVS, 11~14 weeks of gestation) or amniocentesis (15~20 weeks of gestation) and FGFR3 variants are analyzed directly. This allows confirmation or exclusion, and a postnatal management plan can be established in advance according to the results.
Preimplantation genetic testing (PGT): When affected parents plan children, this method is combined with in vitro fertilization to screen out affected embryos and implant only unaffected embryos. Because it can also exclude lethal homozygous embryos (occurring in 25% between two affected parents), it is particularly important when both partners are affected.
Clinical newborn screening: Because patients born with new mutations are often born without prenatal diagnosis, clinical suspicion is raised at birth based on the characteristic appearance (short limbs, macrocephaly, trident hand), and the diagnosis is confirmed with imaging and molecular genetic testing. To detect foramen magnum stenosis early in infancy, brain and cervical spinal cord MRI and polysomnography are recommended within the first year of life.
Diagnosis of achondroplasia proceeds by identifying characteristic clinical and radiologic findings and confirming with molecular genetic FGFR3 variant analysis. Because the diagnostic criteria are clear, clinical diagnosis alone has high reliability in typical cases, but molecular genetic testing is essential in atypical cases or when differential diagnosis is needed.
Clinical diagnostic criteria (typical findings): ① rhizomelic short-limbed short stature, ② macrocephaly and frontal bossing, ③ midface hypoplasia, ④ trident hand, ⑤ lumbar hyperlordosis, ⑥ thoracolumbar kyphosis (infancy), ⑦ genu varum. When several of these findings are present simultaneously, achondroplasia is strongly suspected.
Radiologic diagnosis: On a standard skeletal radiographic examination (skeletal survey), the characteristic findings described above (caudal narrowing of the lumbar interpediculate distance, horizontal iliac wings, short tubular bones, etc.) are confirmed. Bone age is generally normal. Integrated interpretation of prenatal ultrasound findings and neonatal radiographic findings is important for early diagnosis.
Molecular genetic confirmation: The p.G380R variant (c.1138G>A or c.1138G>C) is detected by direct sequencing of FGFR3 exon 10. When typical clinical and radiologic findings are present and p.G380R is confirmed, the diagnosis is confirmed. When p.G380R is negative, rare variants are detected by analysis of the entire FGFR3 gene (NGS-based skeletal dysplasia panel).
Differential diagnosis: Thanatophoric dysplasia — FGFR3 K650E (TDII), R248C, etc., more severe phenotype, perinatally lethal. Hypochondroplasia — FGFR3 N540K, etc., milder phenotype. Chondroectodermal dysplasia (Ellis-van Creveld, Q77.6) — polydactyly, EVC/EVC2 variants. Clinical, radiologic, and molecular genetic differentiation from other skeletal dysplasias must be made.
Evaluation of complications: After confirmation, age-appropriate evaluation of complications should be carried out systematically. Infancy: head and cervical spinal cord MRI (measurement of foramen magnum diameter), polysomnography, head circumference tracking (hydrocephalus evaluation), hearing tests. Childhood: spinal radiographs, measurement of thoracolumbar kyphosis, hearing tests, growth curves (achondroplasia-specific charts). Adolescence and adulthood: lumbar MRI (degree of stenosis), polysomnography, cardiovascular risk assessment. Neurological evaluation: gait analysis, muscle strength and sensory testing, bladder function evaluation.
Treatment of achondroplasia consists of two pillars: correction of the underlying pathogenesis (modulation of FGFR3 signaling) and management of complications. Collaboration of a multidisciplinary team (pediatrics, neurosurgery, orthopedics, otolaryngology, sleep medicine, genetic counselor, psychologist, physical therapist) is essential.
Vosoritide (brand name Voxzogo): The first targeted therapy for achondroplasia, approved by the FDA (US) in 2021 and the EMA (Europe) in 2022. It is a 39-amino-acid analog of CNP (C-type natriuretic peptide) that generates cGMP through the NPR-B receptor and inhibits the ERK pathway downstream of FGFR3, promoting growth of growth plate chondrocytes. It is administered by subcutaneous injection once daily (15 mcg/kg/day) and was approved for children aged 5 years and older with open growth plates (open epiphysis). In a phase 3 clinical trial (ClinicalTrials.gov NCT03197766), the annualized growth velocity improved significantly compared with the placebo group (treatment group +6.0 cm/year vs placebo group +4.1 cm/year). Long-term clinical data on increases in adult height are accumulating, and the effect on final adult height is under continued follow-up. In Korea, review of approval and insurance coverage is in progress.
Limb Lengthening Surgery: Limb lengthening using the Ilizarov method or a motorized intramedullary nail aims to increase final height. The humerus, forearm bones, femur, and tibia are lengthened in stages, allowing a total height increase of 20~35 cm. However, the treatment period is long (multistage surgery over several years), and there are risks of complications (pin infection, joint stiffness, neurovascular injury, refracture), so the decision should be made after sufficient information is provided to the patient and family. Currently, clinical judgment regarding combined use with vosoritide or use alone is made for each patient.
Foramen Magnum Decompression: When cervical spinal cord compression due to foramen magnum stenosis is confirmed in infancy, neurosurgical decompression (partial removal of the occipital bone, duraplasty) is performed. Surgical indications are severe central apnea on polysomnography, neurological symptoms (limb paralysis, hyperreflexia, bladder dysfunction), and spinal cord signal changes on MRI. Early surgery can prevent sudden infant death and allow recovery from neural injury.
Treatment of hydrocephalus: Ventriculoperitoneal shunt or endoscopic third ventriculostomy (ETV) is chosen according to the severity and mechanism of hydrocephalus.
Treatment of spinal stenosis: For lumbar spinal stenosis in adulthood, conservative treatment (physical therapy, NSAIDs, epidural steroid injection) comes first, but surgical decompression (laminectomy, laminoplasty) is needed when there are neurological deficits (lower limb paralysis, voiding dysfunction) or severe claudication.
Otolaryngologic treatment: Insertion of tympanostomy tubes for recurrent otitis media with effusion, adenoidectomy, and use of hearing aids are important for preserving hearing.
Treatment of sleep apnea: Positional therapy and monitoring are used in mild cases, positive airway pressure (CPAP/BiPAP) therapy in moderate or more severe cases, and surgical correction for severe structural abnormalities of the upper airway.
Other investigational therapies: Numerous agents, including Agenacimab, Infigratinib (FGFR3 inhibitor), Transient ossification, and Solicitide, are in clinical trials.
The life expectancy of patients with achondroplasia is almost the same as that of the general population when infantile complications (foramen magnum stenosis, central apnea) are properly managed. Intelligence is normal, and many patients are as active as the general public in education, work, and social participation. However, because various physical complications can affect quality of life, active and continuous multidisciplinary management is needed.
Prognosis in infancy: The most important prognostic determinant is management of foramen magnum stenosis. Without appropriate MRI evaluation and, if needed, neurosurgical decompression, there is a risk of sudden infant death or permanent neurological injury. With early detection and treatment, infant mortality has been greatly reduced. Hydrocephalus progresses to a level requiring shunt surgery in about 5% of all patients.
Growth and development: Before the introduction of vosoritide treatment, mean adult height was 131cm in men and 124cm in women. In children receiving vosoritide treatment, annual height gain is improving significantly, but long-term follow-up data on its effect on final adult height are still accumulating. When limb lengthening is chosen, height increases of up to 35cm have been reported, but there is a risk of surgical complications.
Spinal stenosis and chronic pain: Lumbar spinal stenosis in adulthood is the most common chronic complication, and if it progresses without surgical decompression, there is a risk of neurogenic claudication and lower limb paralysis. Symptom improvement after surgery is reported in most patients, but because stenosis is multilevel and may recur, long-term follow-up is needed.
Hearing and the middle ear: If recurrent otitis media in childhood is not properly treated, permanent conductive hearing loss develops, which can affect language development and academic achievement. Regular hearing tests and otolaryngology follow-up are important.
Sleep and cardiovascular: If sleep apnea is not treated, the long-term risk of cardiovascular complications (hypertension, right ventricular hypertrophy, pulmonary hypertension) increases. After CPAP/BiPAP treatment or upper airway surgery, sleep quality improves and cardiovascular risk also decreases.
Quality of life: Beyond physical complications, social prejudice, self-esteem, and psychological adjustment are important determinants of quality of life. Linkage with patient support groups (the international achondroplasia association LFSA, the Human Growth Foundation, etc.), psychological counseling, and peer networks help psychosocial adjustment.
Primary prevention of achondroplasia (preventing onset itself) is currently possible only through genetic intervention, and secondary and tertiary prevention consist of early detection and active treatment of complications.
Primary prevention — genetic counseling and genetic testing: When there is an affected individual or affected parent, the likelihood of transmission to children and the options are discussed with a genetic counselor. Between two affected parents, a distribution of 25% lethal homozygous, 50% affected heterozygous, and 25% normal is expected, so preimplantation genetic testing (PGT) is strongly recommended. Preimplantation genetic testing checks for the FGFR3 p.G380R variant and homozygosity, allowing implantation of affected embryos (especially homozygous) to be avoided. When a child is born with a new mutation to normal parents, the recurrence risk for the next child is very low (<1%), but the possibility of sporadic occurrence is explained.
Early prenatal diagnosis: When there is an affected parent or abnormal prenatal ultrasound findings, cfDNA-based noninvasive prenatal testing or chorionic villus sampling is performed in early pregnancy (10~14 weeks) to obtain results early and establish a postnatal management plan in advance. This allows a specialized neonatal team to prepare for delivery and respond promptly to infantile complications (foramen magnum stenosis, respiratory failure).
Secondary prevention — early detection of complications: The age-specific examination schedule is followed according to management guidelines for patients with achondroplasia. Brain and cervical spinal cord MRI and polysomnography within 6 months after birth; regular hearing tests (every 6 months~1 year); tracking of height and weight on achondroplasia-specific growth curves; spinal radiographs every 1~2 years; regular lumbar MRI in adulthood.
Tertiary prevention — maintaining quality of life: Recommending low-impact aerobic exercise (swimming, cycling) to prevent obesity and maintain muscle strength; education in correct posture that minimizes spinal load and creation of an ergonomic environment (special furniture and tools); prevention of cardiovascular complications through treatment of sleep apnea; regular ophthalmologic and dental checkups (dental malocclusion and vision problems due to midface hypoplasia); psychosocial support and linkage with patient organizations.
Shirley ED, Ain MC. Achondroplasia: manifestations and treatment. J Am Acad Orthop Surg. 2009;17(4):231-241. PMID: 19307673.
Ornitz DM, Legeai-Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn. 2017;246(4):291-309. DOI: 10.1002/dvdy.24479. PMID: 27987249.
Hoover-Fong J, Scott CI, Jones MC; Committee on Genetics. Health Supervision for People With Achondroplasia. Pediatrics. 2020;145(6):e20201010. DOI: 10.1542/peds.2020-1010. PMID: 32461294.
Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381(1):25-35. DOI: 10.1056/NEJMoa1813446. PMID: 31269546.
Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78(2):335-342. DOI: 10.1016/0092-8674(94)90302-6. PMID: 7913883.
Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371(6494):252-254. DOI: 10.1038/371252a0. PMID: 8078586.
Foreman PK, van Kessel F, van Hoorn R, et al. Birth prevalence of achondroplasia: A systematic literature review and meta-analysis. Am J Med Genet A. 2020;182(10):2297-2316. DOI: 10.1002/ajmg.a.61787. PMID: 32741098.
Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1. DOI: 10.1186/s13023-018-0972-6. PMID: 30606183.
Leiva-Gea A, Delgado-Martos MJ, Martos-Rodríguez A, et al. Lumbar spinal stenosis in achondroplasia: natural history and management. Eur Spine J. 2022;31(8):1943-1951. DOI: 10.1007/s00586-022-07268-5. PMID: 35687190.
Kim SJ, Balce GC, Agashe MV, et al. Is bilateral tibial lengthening appropriate to improve functional outcome in achondroplasia? A systematic review. Clin Orthop Surg. 2012;4(3):178-184. DOI: 10.4055/cios.2012.4.3.178. PMID: 22949968.